Importance and hurdles to drug discovery for neurological disease |
| |
| Authors: | Joseph R. Berger MD Dennis Choi MD PhD Henry J. Kaminski MD Mark F. Gordon MD Orest Hurko MD O'Neill D'Cruz MD MBA Samuel J. Pleasure MD PhD Eva L. Feldman MD PhD |
| |
| Affiliation: | 1. Department of Neurology, University of Kentucky College of Medicine, , Lexington, KY;2. Department of Neurology, Stony Brook School of Medicine, , Stony Brook, NY;3. Department of Neurology, George Washington University Medical Faculty Associates, , Washington, DC;4. Boehringer‐Ingelheim Pharmaceuticals, , Ridgefield, CT;5. Clinical Translational Medicine, , Devon, PA;6. UCB Pharma, , Raleigh, NC;7. Department of Neurology, University of California, San Francisco, , San Francisco, CA;8. Department of Neurology, University of Michigan, , Ann Arbor, MI |
| |
| Abstract: | ![]()
This is a critical time in neurotherapeutics. The prevalence of neurological disease, such as dementia, stroke, and peripheral neuropathy, is large and growing consequent to the aging population. The personal and societal impact of these disorders is enormous, and the number of novel therapies in the pipeline for these disorders has been contracting. Support for the development of neurotherapies must continue from the bench to their ultimate place at the bedside. Academic medicine must continue to play a critical role, in league with industry and government, in the development of novel neurotherapies desperately needed by an ever‐expanding population. Critical steps include the identification and adoption of reliable, valid, and reproducible biomarkers to serve as primary endpoints in clinical trials of neurological disease. Ann Neurol 2013;74:441–446 |
| |
| Keywords: | |
|
|
